Literature DB >> 11934877

IFN-alpha/beta enhances BCR-dependent B cell responses.

Déborah Braun1, Iris Caramalho, Jocelyne Demengeot.   

Abstract

Type I interferon (IFN-I) is constitutively produced in the bone marrow (BM), and induced at sites of inflammation and following infection by viruses or microorganisms. We have previously shown that IFN-I regulates the generation and selection of normal B cell populations in the BM. In the present work, we assess the effects of IFN-I on mature B cell function by monitoring the responses of IFN-alpha/beta-treated murine splenic B cells to apoptotic, mitogenic and activating stimuli. A similar analysis is performed on BM mature B cells obtained from wild-type or IFN-I receptor-deficient mice. IFN-alpha/beta is shown to induce B cells to a state of partial activation characterized by the up-regulation of CD69, CD86 and CD25 molecules in the absence of either proliferation or terminal differentiation. B cells treated with IFN-alpha/beta show an increased survival and resistance to Fas-mediated apoptosis. IFN-alpha/beta also enhances B cell responses to BCR ligation such as calcium fluxes, IgM internalization, induction of activation markers and proliferation. These results indicate that in addition to its inhibitory effect on viral replication and T cell apoptosis, IFN-alpha/beta plays an essential role during an inflammatory response by lowering the threshold for B cell induction, thereby promoting fast and polyclonal antibody responses.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11934877     DOI: 10.1093/intimm/14.4.411

Source DB:  PubMed          Journal:  Int Immunol        ISSN: 0953-8178            Impact factor:   4.823


  83 in total

Review 1.  B cells as therapeutic targets in SLE.

Authors:  Iñaki Sanz; F Eun-Hyung Lee
Journal:  Nat Rev Rheumatol       Date:  2010-06       Impact factor: 20.543

2.  Ligation of CD180 inhibits IFN-α signaling in a Lyn-PI3K-BTK-dependent manner in B cells.

Authors:  Ming You; Guanjun Dong; Fanlin Li; Feiya Ma; Jing Ren; Yujun Xu; Huimin Yue; Ruijing Tang; Deshan Ren; Yayi Hou
Journal:  Cell Mol Immunol       Date:  2015-08-17       Impact factor: 11.530

Review 3.  B Cell Activation and Response Regulation During Viral Infections.

Authors:  Jonathan H Lam; Fauna L Smith; Nicole Baumgarth
Journal:  Viral Immunol       Date:  2020-04-23       Impact factor: 2.257

Review 4.  Should we inhibit type I interferons in sepsis?

Authors:  Tina Mahieu; Claude Libert
Journal:  Infect Immun       Date:  2006-09-25       Impact factor: 3.441

Review 5.  Toll-like receptor-independent triggering of dendritic cell maturation by viruses.

Authors:  Carolina B López; Jacob S Yount; Thomas M Moran
Journal:  J Virol       Date:  2006-04       Impact factor: 5.103

6.  Activation of autoreactive B cells by endogenous TLR7 and TLR3 RNA ligands.

Authors:  Nathaniel M Green; Krishna-Sulayman Moody; Michelle Debatis; Ann Marshak-Rothstein
Journal:  J Biol Chem       Date:  2012-09-27       Impact factor: 5.157

Review 7.  Antitumour actions of interferons: implications for cancer therapy.

Authors:  Belinda S Parker; Jai Rautela; Paul J Hertzog
Journal:  Nat Rev Cancer       Date:  2016-03       Impact factor: 60.716

Review 8.  Thymic Germinal Centers and Corticosteroids in Myasthenia Gravis: an Immunopathological Study in 1035 Cases and a Critical Review.

Authors:  Frédérique Truffault; Vincent de Montpreville; Bruno Eymard; Tarek Sharshar; Rozen Le Panse; Sonia Berrih-Aknin
Journal:  Clin Rev Allergy Immunol       Date:  2017-02       Impact factor: 8.667

Review 9.  Regulation of autoreactive B cell responses to endogenous TLR ligands.

Authors:  Ana Maria Avalos; Liliana Busconi; Ann Marshak-Rothstein
Journal:  Autoimmunity       Date:  2010-02       Impact factor: 2.815

10.  B Cell-Intrinsic STING Signaling Triggers Cell Activation, Synergizes with B Cell Receptor Signals, and Promotes Antibody Responses.

Authors:  Melissa M Walker; Bergren W Crute; John C Cambier; Andrew Getahun
Journal:  J Immunol       Date:  2018-10-03       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.